Salute e Benessere
Implantica publishes Annual Report 2024
Nicole Pehrsson , Chief Corporate Affairs Officer
Telephone (CH): +41 (0)79 335 09 49
nicole.pehrsson@implantica.com
Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm .
The company's Certified Adviser is FNCA Sweden AB, info@fnca.se
Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.
https://www.implantica.com/media/media-kit
Implantica AG
Juanita Eberhart , VP Marketing & Advocacy
M: +1 925-381-4581
juanita.eberhart@implantica.com
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/implantica/r/implantica-publishes-annual-report-2024,c4136011
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/implantica-publishes-annual-report-2024-302428545.html